Top Medical News
Tristan Manalac, 7 hours ago
Obesity appears to decrease the risk of all-cause death in patients receiving statins after acute myocardial infarction, a recent study from Korea has shown.
11 hours ago
Among ageing adult congenital heart disease (ACHD) patients, traditional atherosclerotic risk factors are associated with coronary artery disease (CAD), while ischaemic stroke is related to factors suggesting a cardioembolic aetiology, a multicentre case–control study has found.
Roshini Claire Anthony, Yesterday

The addition of the glucagon-like peptide-1 analogue semaglutide to standard of care resulted in sustained reduction in weight and waist circumference in individuals with type 2 diabetes (T2D) with high cardiovascular risk, according to the phase III SUSTAIN 6* trial presented at EASD 2017.

Yesterday
There is a need for at least 2 consecutive years of 4-month aerobic interval training to chronically enhance metabolic syndrome (MetS; z score), a recent study has found. Blood pressure (BP) that does not fully revert to pretraining values mediates this chronic effect, allowing a cumulative improvement.
Yesterday
Low-level occupational exposure to crystalline silica is associated with increased risk of mortality from respiratory diseases, pulmonary heart disease, lung cancer and ischaemic heart disease, among other complications, a new study has found.
2 days ago
The presence of target organ damage (TOD) in hypertension is more likely to result in blood pressure (BP) elevation, independently of the type of measurement (office or ambulatory, central or peripheral), according to a recent study. Central BP, even monitored during 24 hours, is not better correlated with TOD than peripheral BP.
5 days ago
New drug applications approved by US FDA as of 1 - 15 September 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Special Reports
Dr. Yeo Khung Keong, Dr. Wiwun Tungsubutra, Prof. Peter Collins, 31 Aug 2017
Agents such as beta-blockers and calcium antagonists have been the cornerstone of treatment for stable angina for some time. However, new options are emerging for patients who remain inadequately controlled on conventional therapies. At a recent Menarini-sponsored symposium held during the APSC Congress 2017 in Singapore, three experts discussed the current treatment landscape, as well as changing paradigms and new effective options for patients with symptomatic angina.
23 Aug 2017
Results from a survey presented at the 2017 Asia Pacific Society of Cardiology Congress indicate that 98% of respondents involved in managing patients with hypertension in Singapore recommend home blood pressure monitoring (HBPM) to patients with hypertension. However, a number of barriers remain to the effective use of out-of-office blood pressure (BP) monitoring.
Prof. Peter Collins, Prof. Giuseppe Mancia, Prof. Carolyn Lam, Dr. Choo Gim Hooi, 12 Jul 2017
Coronary artery disease (CAD) is the leading cause of death worldwide and is expected to remain so for the foreseeable future due to both the ageing population and the increasing prevalence of risk factors such as hypertension, dyslipidaemia, and diabetes. CAD is also the primary risk factor in the development of heart failure (HF). At the 2nd Asia Pacific CardioConnect Meeting in Hong Kong sponsored by Menarini, a group of international and regional experts discussed current strategies for managing stable CAD and HF and highlighted areas where patient outcomes may be improved.
25 May 2017
At a recent lunch symposium during the 14th Annual Scientific Meeting of the Malaysian Society of Hypertension, Dr Chow Yok Wai spoke on the importance of patient adherence in the management of hypertension, highlighting the role of combination therapy in improving treatment outcomes.
24 Apr 2017
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used to treat pain and inflammation in patients with arthritis, but the vascular effects of some NSAIDs have cast doubt on whether they can be used in patients at risk for cardiovascular (CV) disease. At the American Heart Association’s Scientific Sessions 2016 held recently in New Orleans, Louisiana, US, Professor Steven Nissen of the Cleveland Clinic in Cleveland, Ohio, US, presented latest data from the PRECISION (Prospective Randomized Evaluation of Celecoxib Integrated Safety vs Ibuprofen or Naproxen) trial that evaluated the CV risk and safety profile of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib vs nonselective NSAIDs.
16 Mar 2017
Recently, Dr Peter Lin of the Canadian Heart Research Centre spoke on treatment strategies in the management of dyslipidaemia and T2DM at an AstraZeneca-sponsored continuing medical education event. Highlights of his presentations are summarized below.
07 Mar 2017
At the 17th Malaysian Society of Rheumatology/Singapore Society of Rheumatology Workshop, Associate Professor Susanna Proudman, a senior consultant in rheumatology from Australia, shared with the audience on the diagnosis and management of pulmonary arterial hypertension (PAH), with a focus on systemic sclerosis (SSc)-related PAH.
Conference Reports
Dr. Joseph Delano Fule Robles, 06 Sep 2017

The practice of giving oxygen to patients with MI is challenged by a recent registry-based randomized clinical trial showing that this widely accepted practice does not improve survival, according to results presented at the European Society of Cardiology Congress 2017 (ESC 2017) held in Barcelona, Spain. 

Christina Lau, 06 Sep 2017

In patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor significantly reduces bleeding vs triple therapy with warfarin, a P2Y12 inhibitor and aspirin, with comparable rates of thromboembolic events, results of the RE-DUAL PCI trial have shown.

Elaine Tan, 05 Sep 2017

Late-breaking results from a multinational trial show for the first time that adding anacetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, to intensive statin therapy reduces cardiovascular (CV) events in high-risk patients, with the possibility of providing greater benefit with longer duration of treatment. 

Jackey Suen, 04 Sep 2017

Blocking the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) with one to two injections of small interfering RNA (siRNA) provides sustained LDL-cholesterol (LDL-C) lowering for up to 1 year in patients with high cardiovascular (CV) risk and elevated LDL-C levels, the phase II ORION-1 study has shown.

Naomi Rodrig, 04 Sep 2017

Late-breaking data presented at the European Society of Cardiology Congress 2017 in Barcelona, Spain have shown that ibuprofen is associated with greater increase in blood pressure (BP) than celecoxib or naproxen in patients with arthritis, potentially increasing their risk of cardiovascular (CV) events. [Eur Heart J 2017, doi: 10.1093/eurheartj/ehx508]

Naomi Rodrig, 04 Sep 2017

Very aggressive reduction of LDL-cholesterol with the proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor evolocumab was associated with progressively fewer cardiovascular (CV) events without compromising safety in patients with established atherosclerotic disease, according to a secondary analysis of the FOURIER trial (Further Cadiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) presented recently at the European Society of Cardiology Congress 2017 in Barcelona, Spain. [Lancet 2017, doi: 10.1016/S0140-6736(17)32290-0]  

Jenny Ng, 04 Sep 2017

Landmark results from the CASTLE-AF trial has demonstrated that catheter ablation significantly improves outcomes in patients with heart failure and atrial fibrillation (AF), reducing the risk of all-cause mortality and hospitalizations for worsening heart failure by more than one-third compared with conventional treatment. 

Product Highlights
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
DOWNLOAD